1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,383 | 0,387 | 13:07 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Mauna Kea Technologies Reports New Evidence Highly Supportive of the Use of Cellvizio for Diagnosing Pancreatic Cysts Presented at DDW 2024 | 260 | Business Wire | Pancreatic cancer remains difficult to diagnose accurately using conventional methods often leading to late-stage diagnoses or unnecessary surgeries New publications confirm once more Cellvizio's... ► Artikel lesen | |
| 07.06. | Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 6, 2024 | 188 | Business Wire | All the resolutions proposed by the Board of Directors were adopted
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and... ► Artikel lesen | |
| 06.06. | Mauna Kea Technologies Announces Joint Venture in China Obtained Class II Medical Device Business License | 250 | Business Wire | JV now operational to start selling products in China
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based... ► Artikel lesen | |
| 30.05. | Mauna Kea Technologies Winner of "Best New Technology Solution - Oncology" MedTech Breakthrough Award | 199 | Business Wire | Prestigious international program recognizes standout digital health medical technology products and companies 2024 awards program included more than 4,500 nominations from all around the world
Regulatory... ► Artikel lesen | |
| 21.05. | Mauna Kea Technologies Announces the Availability of Preparatory Documents for the Combined General Meeting of June 6, 2024 and the Instructions for Participation | 245 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 17.05. | Mauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capital | 273 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 06.05. | Mauna Kea Technologies Announces 9 Presentations Demonstrating the Clinical Value of Cellvizio at Digestive Disease Week 2024 | 238 | Business Wire | AI, pancreatic cancer and food intolerance headline wide range of Cellvizio abstracts at gastroenterology's largest international meeting
Regulatory News:
Mauna Kea Technologies (Euronext... ► Artikel lesen | |
| 30.04. | Mauna Kea Technologies: Publication of the 2023 Annual Financial Report | 237 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform... ► Artikel lesen | |
| 29.04. | Mauna Kea Technologies Announces the Opening of a French Center of Excellence for the Use of Cellvizio in Lung Cancer Diagnostics | 197 | Business Wire | Cellvizio utilization continues to expand globally in established and emerging clinical indications
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor... ► Artikel lesen | |
| 25.04. | Mauna Kea Technologies Reports Full Year 2023 Results and Q1 2024 Sales | 300 | Business Wire | Full Year 2023 Sales increased +42%1 to €10.5m €1.2m positive full-year operating income +47% growth in Q1 2024 in U.S. PPU volume Recent Telix strategic investment and restructured EIB... ► Artikel lesen | |
| 24.04. | Mauna Kea Technologies Executes Agreement to Restructure its Existing Loan Agreement with the European Investment Bank | 296 | Business Wire | Renewed EIB confidence in Mauna Kea extending support until 2029 Final maturities deferred 4 years to 2028 and 2029 Alignment of debt maturities with the Group's trajectory of profitability... ► Artikel lesen | |
| 04.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 208 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 02.04. | Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio to Identify and Treat Food Intolerance in Adults | 311 | Business Wire | Italy becomes the third country to launch a Cellvizio Center of Excellence following the Metrodora Institute in the U.S. and several other centers in Germany Another key milestone in a global... ► Artikel lesen | |
| 27.03. | Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio | 330 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, and V7... ► Artikel lesen | |
| 06.03. | Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio to Identify and Treat Food Intolerance in Adults | 278 | Business Wire | Cellvizio Food Intolerance Test (C-FIT) delivers real-time, in vivo visibility to accurately identify food intolerance in patients suffering from Irritable Bowel Syndrome (IBS) Metrodora will... ► Artikel lesen | |
| 05.03. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 203 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 07.02. | Mauna Kea Technologies Welcomes Benoit Chardon as Senior Advisor to Scale its Irritable Bowel Syndrome and Food Intolerance Business | 300 | Business Wire | Mr. Chardon is a recognized commercialization expert with a successful track record in new category creation in the health wellness industry
Regulatory News:
Mauna Kea Technologies (Euronext... ► Artikel lesen | |
| 05.02. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 421 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT)
Listing: Euronext Growth Paris
ISIN code:... ► Artikel lesen | |
| 01.02. | Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate | 305 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces... ► Artikel lesen | |
| 31.01. | MAUNA KEA TECHNOLOGIES: Half-Year Liquidity Contract Statement for H2 2023 with the Brokerage Firm Gilbert Dupont | 326 | Business Wire | Regulatory News:
Under the liquidity contract between the company MAUNA KEA TECHNOLOGIES (Paris:ALMKT) and the brokerage firm Gilbert Dupont, the following resources appeared on the liquidity account... ► Artikel lesen |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA | 0,230 | +1,14 % | Sernova Corp: Sernova cancels public offering | ||
| VITA 34 | 4,720 | 0,00 % | Original-Research: Vita 34 AG (von Montega AG): Halten | Original-Research: Vita 34 AG - von Montega AG Einstufung von Montega AG zu Vita 34 AG Unternehmen: Vita 34 AG ISIN: DE000A0BL849 Anlass der Studie: Update Empfehlung: Halten seit: 04.06.2024... ► Artikel lesen | |
| GERATHERM MEDICAL | 4,220 | +0,96 % | EQS-AFR: Geratherm Medical AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Geratherm Medical AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Geratherm Medical AG: Vorabbekanntmachung... ► Artikel lesen | |
| PLUS THERAPEUTICS | 1,950 | +10,67 % | Plus Therapeutics Inc.: Plus Therapeutics Announces New Employment Inducement Grants | AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,006 | -4,01 % | Atossa Therapeutics, Inc.: Atossa Set to Join Russell 3000® Index Effective June 28, 2024 | ||
| MEDICLIN | 2,440 | 0,00 % | EQS-News: MEDICLIN AG: Ordentliche Hauptversammlung der MEDICLIN AG stimmt allen Beschlussvorschlägen zu | EQS-News: MEDICLIN AG
/ Schlagwort(e): Hauptversammlung
MEDICLIN: Ordentliche Hauptversammlung der MEDICLIN AG stimmt allen Beschlussvorschlägen zu
10.06.2024 / 09:48 CET/CEST
Für... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the First Quarter of 2024 | SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 0,163 | -10,66 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results | Revenues increased 14% in Q4 2024 compared to Q4 2023Gross profit margin improved 3% in FY 2024 compared to FY 2023Net loss improved 18% in Q4 2024 compared to Q4 2023, and 6% in FY 2024 compared to... ► Artikel lesen | |
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc.: NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform | CLEVELAND, OH / ACCESSWIRE / May 21, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a pioneering biomedical company developing innovative immunotherapies for brain tumor patients, today announced it has... ► Artikel lesen | |
| REWALK ROBOTICS | 4,078 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.05.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 21.05.2024.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.05.2024.ISIN NameCA00379L1067 ABRASILV.... ► Artikel lesen | |
| VERU | 0,738 | -1,60 % | Veru Inc.: Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024 | ||
| DIASORIN | 98,30 | -0,16 % | Milan: Major selling for DiaSorin | ||
| PROGYNY | 25,730 | 0,00 % | Pre-market Movers: Novavax, MacroGenics, AEye, Sensus Healthcare, Progyny | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Novavax, Inc. (NVAX) is up over 108% at $9.30.
AEye... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 65,20 | -1,81 % | Carl Zeiss Meditec -11%: Das sorgt für den Absturz | Die Aktie von Carl Zeiss Meditec (WKN: 157484) gerät am Montag wegen dieser Nachrichten so stark unter Druck, dass der MDAX-Wert zweistellig abstürzt. Was steckt dahinter? Jahresprognose abgesenkt Wegen... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 52,14 | -0,57 % | Siemens Healthineers nets European approval for blood test to predict MS relapse risks |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +3,55 % bei einem Aktienkurs von 0,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
